ASRT trades 3.6% above Wall Street's consensus target of $22.65.
Last 12 months price action with 12-month analyst target path
The base valuation assumes ASRT achieves its forward estimates and maintains a stable P/E multiple of historical averagesx. This scenario reflects the blended consensus of 18 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
As of June 22, 2026, Assertio Holdings, Inc. (ASRT) has a Wall Street consensus price target of $22.65, based on estimates from 18 covering analysts. With the stock currently trading at $23.50, this represents a potential downside of -3.6%. The company has a market capitalization of $152M.
Analyst price targets range from a low of $21.80 to a high of $23.50, representing a 8% spread in expectations. The median target of $22.65 aligns closely with the consensus average. The tight target dispersion indicates high conviction among analysts.
The current analyst consensus rating is Hold, with 8 analysts rating the stock as a Buy or Strong Buy,9 rating it Hold, and 1 rating it Sell or Strong Sell. The mixed ratings reflect uncertainty about near-term direction.
From a valuation perspective, ASRT trades at a trailing P/E of -5.0x. Analysts expect EPS to grow +69.5% over the next year.
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
PAHCPhibro Animal Health Corporation | $1.3B | $31.85 | $49.00 | +53.8% | Buy | 10.4x | 14 |
AMRXAmneal Pharmaceuticals, Inc. | $5.1B | $16.21 | $17.33 | +6.9% | Buy | 16.5x | 16 |
SUPNSupernus Pharmaceuticals, Inc. | $2.6B | $44.38 | $60.00 | +35.2% | Buy | 17.8x | 14 |
PRGOPerrigo Company plc | $1.4B | $10.25 | $36.20 | +253.2% | Hold | 4.8x | 36 |
COLLCollegium Pharmaceutical, Inc. | $1.1B | $33.54 | $58.00 | +72.9% | Buy | 4.3x | 12 |
HRMYHarmony Biosciences Holdings, Inc. | $1.9B | $33.28 | $43.00 | +29.2% | Buy | 9.7x | 13 |
AVDLAvadel Pharmaceuticals plc | $2.1B | $21.64 | $21.43 | -1.0% | Buy | 28.3x | 14 |
BHCBausch Health Companies Inc. | $1.8B | $4.77 | $8.00 | +67.7% | Buy | 1.1x | 38 |
TEVATeva Pharmaceutical Industries Limited | $36.7B | $31.48 | $40.00 | +27.1% | Buy | 14.4x | 46 |
PCRXPacira BioSciences, Inc. | $878M | $22.33 | $32.00 | +43.3% | Hold | 7.8x | 36 |
Quick answers to the most common questions about buying ASRT stock.
Wall Street's consensus price target for ASRT is $22.65, -3.6% from its current price of $23.5. The below-market target from 18 analysts suggests limited near-term appreciation.
ASRT has a consensus rating of "Hold" based on 18 Wall Street analysts. The rating breakdown is mixed, with 9 Hold ratings making up the largest segment. The consensus 12-month price target of $22.65 implies -3.6% downside from current levels.
ASRT's current price is $23.5 with a consensus target of $22.65 (-3.6% implied move). Analyst estimates suggest the stock is fairly valued at current levels.
The most bullish Wall Street analyst has a price target of $23.5 for ASRT, while the most conservative target is $21.8. The consensus of $22.65 represents the median expectation. These targets typically reflect 12-month expectations.
ASRT is well covered by analysts, with 18 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 8 have Buy ratings, 9 recommend Hold, and 1 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month ASRT stock forecast based on 18 Wall Street analysts shows a consensus price target of $22.65, with estimates ranging from $21.8 (bear case) to $23.5 (bull case). The median consensus rating is "Hold".
Analysts are cautious on ASRT, with 1 Sell ratings and a price target of $22.65 (-3.6% from current price). The "Hold" consensus suggests careful evaluation before buying. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
ASRT analyst price targets range from $21.8 to $23.5, a 8% tight range reflecting strong analyst consensus. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $22.65 consensus represents the middle ground.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.